We investigated the effects of the angiotensin-converting enzyme inhibitor captopril on neurologic outcome in a rat model of incomplete cerebral ischemia. Twenty male SpragueDawley rats were anesthetized with 70% nitrous oxide in oxygen and fentanyl (10/igxkg" 1 i.v. bolus, 25 /*gxkg~'xhr~1 i.v. continuous infusion). Animals in group 1 (n=10) received no angiotensin-converting enzyme inhibitor while animals in group 2 (n=10) were given 10 mgxkg" 1 i.v. captopril 30 minutes prior to the ischemic period. Ischemia was produced by unilateral carotid artery ligation and hemorrhagic hypotension to 35 mm Hg for 30 minutes. Body temperature, arterial blood gases, and arterial pH were maintained constant Neurologic outcome was evaluated every 24 hours for 3 days using a graded deficit score (0, normal; 18, stroke-related death). On the third day after ischemia, captopril significantly improved neurologic outcome (median deficit score=4) compared with controls (median deficit score=18) (p<0.05). These results suggest that reduced angjotensin II levels or increased tissue kinin concentrations may decrease ischemic brain injury. (Stroke 1991;22:910-914) C ontroversy exists on the influence of the brain renin-angiotensin system 12 in the modulation of cerebral ischemia. Studies in strokeprone spontaneously hypertensive rats and gerbils suggest that the administration of angiotensin-converting enzyme inhibitors reduce stroke-related mortality and neurologic symptoms. 34 In contrast, experiments on unilateral brain ischemia in gerbils demonstrate a reduction of stroke-related mortality in the presence of angiotensin II. 5 The protective effect of angiotensin II could be reversed using angiotensin-converting enzyme inhibitors or angiotensin II antagonists. 6 These results may be due in part to the cardiovascular effects of the drugs. The hypotensive effect of angiotensin-converting enzyme inhibitors may improve outcome from hypertensive stroke while angiotensin II may increase blood pressure and enhance cerebral perfusion during focal ischemia. We investigated the effect of the angiotensin-converting enzyme inhibitor captopril on neurologic outcome in a model of incomplete cerebral ischemia in rats.
C ontroversy exists on the influence of the brain renin-angiotensin system 12 in the modulation of cerebral ischemia. Studies in strokeprone spontaneously hypertensive rats and gerbils suggest that the administration of angiotensin-converting enzyme inhibitors reduce stroke-related mortality and neurologic symptoms. 34 In contrast, experiments on unilateral brain ischemia in gerbils demonstrate a reduction of stroke-related mortality in the presence of angiotensin II. 5 The protective effect of angiotensin II could be reversed using angiotensin-converting enzyme inhibitors or angiotensin II antagonists. 6 These results may be due in part to the cardiovascular effects of the drugs. The hypotensive effect of angiotensin-converting enzyme inhibitors may improve outcome from hypertensive stroke while angiotensin II may increase blood pressure and enhance cerebral perfusion during focal ischemia. We investigated the effect of the angiotensin-converting enzyme inhibitor captopril on neurologic outcome in a model of incomplete cerebral ischemia in rats.
Materials and Methods
Following approval from the Institutional Animal Care Committee, 20 nonfasted male Sprague-Dawley rats weighing 330-420 g were anesthetized in a bell jar with isoflurane, their tracheas were intubated, and their lungs were mechanically ventilated with 2% isoflurane in 30% oxygen and air. Catheters were inserted into both femoral arteries and veins for continuous blood pressure measurement and for blood sampling and drug administration. A catheter was inserted into the right jugular vein for blood withdrawal during ischemia. The right common carotid artery was isolated, and a loose ligature was placed around the vessel for later clamping. Vecuronium was given as a continuous infusion at 0.1 mgxkg~1xmirr 1 to maintain paralysis. At the completion of surgery, the incisions were infiltrated with 0.25% bupivacaine. Isoflurane was removed from the inspiratory gas mixture, and the rats were equilibrated for 30 minutes according to one of the following group treatments. Rats in group 1 (n = 10) received 70% nitrous oxide (N 2 O) in oxygen and a bolus of fentanyl (10 ^gxkg" 1 i.v.) followed by a continuous infusion of fentanyl (25 /xgxkg~'xhr~1). Rats in group 2 (n = 10) received 70% N 2 O in oxygen, a bolus of fentanyl (10 ^igxkg" 1 i.v.) followed by a continuous infusion of fentanyl (25 ^gxkg" 1 xhr" 1 ), plus intravenous captopril (10 mgxkg" 1 ) 30 minutes prior to the ischemic period.
Cerebral ischemia was produced by the combination of right common carotid artery occlusion and and fentanyl were discontinued 30 minutes after the reinfusion. During recovery, the catheters were removed and the incisions were closed. The rats were extubated and transferred to their home cages.
Neurologic outcome was scored by a blinded investigator every 24 hours for 3 days, starting 24 hours after ischemia. Table 1 shows the six categories of performance evaluated by neurologic examination. For the total examination, a score of 0 represented no detectable neurologic deficit and a score of 18 represented stroke-related death. Stroke-related death was determined after a minimum of 3 hours following extubation only if the rat showed progressive signs of stroke impairment.
Data are reported as mean±SEM. Nonparametric data including neurologic outcome score were evaluated using a signed rank test. Arterial blood pressure, blood gas tensions, and pH were compared between groups using two-way analysis of variance and Tukey's test for post hoc comparisons. Spearman's rank-order correlation was used to compare neurologic outcome score with plasma glucose concentration. The level of significance was/?<0.05.
Results
Captopril produced an approximately 25% decrease in blood pressure before ischemia (Table 2) . According to the protocol, arterial blood pressure was decreased to 35 mm Hg in both groups during ischemia. Arterial blood pressure remained reduced by 25% in group 2 compared with group 1 during recovery. Plasma glucose concentration increased significantly during ischemia in both groups and remained elevated during recovery in group 2. Arterial blood gases and pH did not change over time.
In group 1, ischemia produced stroke-related death in one rat (10%) on day 1, four rats (40%) on day 2, and six rats (60%) on day 3. Neurologic deficits were moderate to severe in all other rats (Figure 1) . In group 2, stroke-related death was seen in one rat (10%) on day 1 and in two rats (20%) on days 2 and 3. Neurologic outcome score was significantly reduced in group 2 compared with group 1 (p<0.02). The correlation between intraischemic plasma glucose concentration and neurologic outcome score was not significant (r=0.1, p>0.05).
Discussion
The controversy concerning the renin-angiotensinaldosterone system and stroke 1 -2 has been evaluated in stroke-prone spontaneously hypertensive rats or during unilateral brain ischemia in gerbils. 3 -6 These studies have shown that high or low concentrations of angiotensin II can be associated with either increases or decreases in stroke-related mortality. The effects of angiotensin-converting enzyme inhibition on neurologic outcome in a model of incomplete cerebral ischemia with control of important physiological variables have never been studied. Our results indicate that treatment with the angiotensin-converting enzyme inhibitor captopril improved neurologic outcome following incomplete cerebral ischemia. The improved outcome could not be explained by differences in body temperature, arterial blood gases, or pH, which were maintained at physiological levels during the experiment. These results support studies in which angiotensin-converting enzyme inhibition improved outcome from cerebral and myocardial ischemia 34 ' 7 -8 and suggest involvement of the reninangiotensin cascade or the kinin system in the modulation of ischemic brain damage.
The mechanism by which angiotensin-converting enzyme inhibition decreases ischemic neuronal damage is not" known. Captopril reduces arterial blood pressure by decreasing circulating angiotensin II concentrations and increasing plasma kinin concentrations. 9 It has been shown that the level of arterial blood pressure during and after ischemia is an important factor in the modulation of infarct size and the development of hypertensive hemorrhage. 1011 Cole et al 10 have shown in a rat model of focal ischemia that hypertension during reperfusion increases intraparenchymal hemorrhage in the injured area. Drummond et al 11 have shown that phenylephrine-induced hypertension to 134 mm Hg during ischemia improves perfusion of focal ischemic brain areas in rats without producing hemorrhage. It is possible that captopril improved outcome in our studies by decreasing hypertension-induced hemorrhage during the postischemic period. However, the effects of arterial hypertension on the occurrence of hemorrhage during reperfusion may be less significant in models using incomplete ischemia where cerebral blood flow (CBF) is still present within the ischemic territory. 12 This injurious mechanism may be more important following focal or near-complete ischemia when the cerebral vasculature within the ischemic tissue is exposed to acute increases in transmural pressure with the beginning of reperfusion. 10 The total amount of blood withdrawn for blood gas and glucose analyses was < 2 ml in each rat. Since this is <10% of a rat's blood volume, it is unlikely that this contributed significantly to captopril-induced hypotension.
Under normal conditions, the passage of intravenous captopril through the intact blood-brain barrier is neglible. 13 However, Kuroiwa et al 14 found that ischemia produces a transient opening of the bloodbrain barrier, which would allow passage of captopril into the brain. Additionally, opening of the bloodbrain barrier may be earlier and more severe in models using temporary ischemia and reperfusion. 15 It is therefore possible that neurologic outcome may be improved by central as well as peripheral angiotensin-converting inhibition in our experiments..
Angiotensin-converting enzyme is active in converting angiotensin I to angiotensin II and in breaking down bradykinin and tissue kinins to inactive metabolites. 9 Studies in vitro and in vivo have shown that angiotensin II is a potent cerebral vasoconstrictor, contracting smooth muscle directly 16 -18 and indirectly 2-19 by potentiating catecholamine release from sympathetic neurons. Angiotensin II in high concentrations may decrease CBF during ischemia and contribute to ischemic neuronal damage.
318 Consistent with this, studies by Waldemar 20 and Waldemar and Paulson 21 showed that angiotensin-converting enzyme inhibitors increase CBF at lower blood pressure levels. Rajagopalan et al 22 have suggested that captopril may increase CBF in patients with congestive heart failure by decreasing central sympathetic tone. This was questioned by several other workers who failed to demonstrate changes in CBF following angiotensin-converting enzyme inhibition.
-
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' 23 Previous results in ischemia studies may be related to the direct cardiovascular effects of angiotensin II or angiotensin-converting enzyme inhibition. In models using stroke-prone hypertensive rats, angiotensinconverting enzyme inhibitors may modulate stroke by decreasing blood pressure. On the other hand, the administration of angiotensin II may be protective during focal cerebral ischemia in gerbils by increasing blood pressure and collateral blood flow. 56 Neither mechanism is probably important in our study since blood pressure was controlled during ischemia. A lower cerebral perfusion pressure in captopriltreated rats after ischemia may exacerbate postischemic cerebral hypoperfusion. 11 However, the better outcome in captopril-treated rats suggests that this was not a major factor.
The improvement of neurologic outcome following incomplete cerebral ischemia in captopril-treated rats is consistent with reports on myocardial ischemia. Studies using the isolated ischemic heart preparation have shown that angiotensin-converting enzyme inhibitors improve myocardial perfusion, attenuate catecholamine release, and decrease the magnitude of cellular injury. 7 -8 This suggests a link between angiotensin II and catecholamine release in worsening myocardial ischemic outcome. 24 Major components of the brain angiotensin II system and central catecholamines are anatomically and functionally related, and there is evidence that angiotensin II stimulates the central release of catecholamines and other excitatory neurotransmitters. 2 -9 Reduction in the concentrations of these neurotransmitters with captopril improves outcome from transitory cerebral ischemia in gerbils. 4 In this model of ischemia, elevated plasma glucose concentrations protect the brain from energy depletion but worsen long-term ischemic neuronal damage and neurologic outcome. 25 In the present experiments, captopril-treated rats had lower plasma glucose concentrations prior to ischemia and higher plasma glucose concentrations during reperfusion. However, there was no significant difference in plasma glucose concentration during ischemia, when glucose delivery was probably critical. It is likely that glucose delivery and aerobic metabolism were adequate during reperfusion in both groups. This suggests that other mechanisms besides differences in preischemic or postischemic plasma glucose concentrations improved the neurologic outcome in captopril-treated rats. 26 One potential problem of the present experiment is the measurement and maintenance of body temperature at 37°C. Busto et al 27 have found using the four-vessel occlusion model that intraischemic temperature of the temporal muscle reflects temperature obtained from striatal sites of the brain. In our model of incomplete hemispheric ischemia, pilot observations have shown a close correlation between rectal and temporal muscle temperatures when an overhead heat lamp was used. Since the rats were treated the same in both groups, it is likely that brain temperature did not differ between animals during the present experiments.
It is concluded that the angiotensin-converting enzyme inhibitor captopril improves neurologic outcome from incomplete cerebral ischemia in rats. Possible mechanisms include attenuation of the direct vasoconstrictor effects of angiotensin II during ischemia, a decrease in the potentiation of catecholamines and other central excitatory neurotransmitters, or an increase in the local concentration of kinins.
